The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of A-101 Topical Solution for the Treatment of Common Warts
Official Title: A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
Study ID: NCT03812510
Brief Summary: A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
Detailed Description: A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Aclaris Investigational Site, Mobile, Alabama, United States
Aclaris Investigational Site, Glendale, Arizona, United States
Aclaris Investigational Site, Fort Smith, Arkansas, United States
Aclaris Investigational Site, Hot Springs, Arkansas, United States
Aclaris Investigational Site, Encinitas, California, United States
Aclaris Investigational Site, Fountain Valley, California, United States
Aclaris Investigational Site, San Diego, California, United States
Aclaris Investigational Site, San Diego, California, United States
Aclaris Investigational Site, Denver, Colorado, United States
Aclaris Investigational Site, Aventura, Florida, United States
Aclaris Investigational Site, Jacksonville, Florida, United States
Aclaris Investigational Site, Miami, Florida, United States
Aclaris Investigational Site, Miami, Florida, United States
Aclaris Investigational Site, Ocala, Florida, United States
Aclaris Investigational Site, Newnan, Georgia, United States
Aclaris Investigational Site, Indianapolis, Indiana, United States
Aclaris Investigational Site, New Albany, Indiana, United States
Aclaris Investigational Site, Louisville, Kentucky, United States
Aclaris Investigational Site, Rockville, Maryland, United States
Aclaris Investigational Site, Fridley, Minnesota, United States
Aclaris Investigational Site, Saint Joseph, Missouri, United States
Aclaris Investigational Sites, Omaha, Nebraska, United States
Aclaris Investigational Site, Las Vegas, Nevada, United States
Aclaris Investigational Site, Verona, New Jersey, United States
Aclaris Investigational Site, Rochester, New York, United States
Aclaris Investigational Site, Raleigh, North Carolina, United States
Aclaris Investigational Site, Beachwood, Ohio, United States
Aclaris Investigational Site, Bexley, Ohio, United States
Aclaris Invesgational Site, Broomall, Pennsylvania, United States
Aclaris Investigational Site, Fort Washington, Pennsylvania, United States
Aclaris Investigational Site, Upper Saint Clair, Pennsylvania, United States
Aclaris Investigational Site, Anderson, South Carolina, United States
Aclaris Investigational Site, Charleston, South Carolina, United States
Aclaris Investigational Site, Fountain Inn, South Carolina, United States
Aclaris Investigational Site, Knoxville, Tennessee, United States
Aclaris Investigational Site, Nashville, Tennessee, United States
Aclaris Investigational Site, Arlington, Texas, United States
Aclaris Investigational Site, Austin, Texas, United States
Aclaris Investigational Site, College Station, Texas, United States
Aclaris Investigational Site, Houston, Texas, United States
Aclaris Investigational Site, Pflugerville, Texas, United States
Aclaris Investigational Site, San Antonio, Texas, United States
Aclaris Investigational Site, Lynchburg, Virginia, United States
Aclaris Investigational Site, Norfolk, Virginia, United States
Aclaris Investigational Site, Norfolk, Virginia, United States
Aclaris Investigational Site, Spokane, Washington, United States
Name: David Gordon, MB, ChB
Affiliation: Aclaris Therapeutics
Role: STUDY_DIRECTOR